As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company

Ever since disappointing late-stage data on its cancer drug tanked Idera Pharmaceuticals’ stock last year (unhelped by an ill-fated collaboration with AbbVie), execs have been tightening the belt while searching for something — anything — that may dig the company out of its hole.